The effect of graft-versus-host disease (GVHD) on relapse incidence and survival has been analyzed in several studies, but previous studies included heterogeneous patients. Therefore, we analyzed the data of 2114 patients who received unmanipulated bone marrow graft from an HLA-identical sibling donor with a GVHD prophylaxis using cyclosporin A and methotrexate. Among the 1843 patients who survived without relapse at 60 days after transplantation, 435 (24%) developed grade II-IV acute GVHD. Among the 1566 patients who survived without relapse at 150 days after transplantation, 705 (47%) developed chronic GVHD. The incidence of relapse was significantly lower in patients who developed acute or chronic GVHD, but disease-free survival (DFS) was significantly inferior in patients who developed acute GVHD. A benefit of 'mild' GVHD was only seen in high-risk patients who developed grade I acute GVHD. The strongest association between GVHD and a decreased incidence of relapse was observed in patients with standard-risk acute myelogenous leukemia/myelodysplastic syndrome. In conclusion, the therapeutic window between decreased relapse and increased transplant-related mortality due to the development of GVHD appeared to be very narrow.
Introduction
Graft-versus-host disease (GVHD) is the main cause of treatment failure after allogeneic hematopoietic stem cell transplantation (HSCT). On the other hand, an antitumor effect induced by GVHD, the so-called graft-versus-leukemia (GVL) effect, was recognized in the 1970s. 1, 2 The impact of GVHD on relapse incidence and survival has been analyzed in several large studies. [1] [2] [3] [4] [5] [6] [7] While GVHD has an apparent antitumor effect, the positive effect is counterbalanced by increased transplantrelated mortality, which generally results in a worse transplant outcome in patients who develop GVHD, although two studies have suggested that 'mild' GVHD confers a survival benefit. 4, 7 Previous studies included heterogeneous patients with regard to donor source, ex vivo graft manipulation, and the GVHD prophylaxis regimen. Such differences may have affected analyses of the GVL effect. In addition, recent advances in supportive treatments may have improved the outcome of patients who developed GVHD. Therefore, the aim of this study was to re-evaluate the influence of GVHD on bone marrow transplant outcome in non-T-cell-depleted transplantation from an HLA-identical sibling donor, which was performed between 1991 and 2000 with a GVHD prophylaxis using cyclosporin A (CsA) and methotrexate.
Materials and methods

Study population
The Japan Society for Hematopoietic Cell Transplantation (JSHCT) collects data from each transplant center by means of the standardized report form. The follow-up reports were submitted annually after transplantation. A total of 3356 patients, who underwent allogeneic HSCT for the first time between 1991 and 2000 for chronic myelocytic leukemia (CML), acute myeloblastic leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS), were reported to the JSHCT. 8 Only patients who received bone marrow graft from an HLA-identical sibling donor using a GVHD prophylaxis regimen consisting of CsA and methotrexate were included in this study. Those less than 16 years old, those who received graft from a syngeneic donor, those who received manipulated graft, those who received a reduced-intensity/ nonmyeloablative conditioning, and those who received peripheral blood or cord blood graft were excluded. Finally, the data on August 2001 of 2114 patients were analyzed. This study was approved by the Committee for Nationwide Survey Data Management of JSHCT.
Transplantation procedure
The conditioning regimen before HSCT was either a total body irradiation-based regimen (61%, mainly combined with cyclophosphamide) or a chemotherapy-based regimen (39%, mainly a combination of busulfan and cyclophosphamide). Acute and chronic GVHD were scored according to the traditional Seattle criteria.
9,10
Statistical considerations
Engraftment was defined as a neutrophil count greater than 500/ mm 3 for 3 consecutive days. Engraftment failure was diagnosed as when engraftment was not achieved at any time after transplantation. Disease-free survival (DFS) was defined as days from a landmark point (described below) to disease relapse or death from any cause. Nonrelapse mortality was defined as death without relapse. Patients who were alive at the last followup date were censored. DFS was calculated using the KaplanMeier method. To evaluate the influence of confounding factors for acute GVHD and survival, the log-rank test and proportionalhazards modeling were used for univariate and multivariate analyses, respectively. Cumulative incidences of relapse and nonrelapse mortality were calculated using Gray's method, considering each other event as a competing risk. 11 Effects of acute and chronic GVHD on DFS and relapse were analyzed among patients who achieved engraftment and were surviving without relapse at 60 and 150 days after transplantation, respectively. 2, 5 This landmark method was used to exclude bias that may have arisen from including patients who died or had a relapse too early to develop GVHD in the group without GVHD. 12, 13 Potential confounding factors considered in the analysis were recipient age, sex, disease status, year of transplantation, and conditioning regimen. Factors associated with at least borderline significance (Po0.10) in the univariate analysis were subjected to a multivariate analysis using backward stepwise selection of covariates. All P-values were twosided and P-values of 0.05 or less were considered statistically significant.
Acute leukemia in first or second remission, CML in first or second chronic phase, and MDS without leukemic transformation were considered standard-risk diseases, while others were considered high-risk diseases. The effect of acute GVHD was evaluated by comparing grade 0-I vs grade II-IV acute GVHD, except for the evaluation of the effect of 'mild GVHD'.
Results
Characteristics of the patients
The characteristics of the patients are summarized in Table 1 . The underlying disease was AML in 737 (35%), ALL in 498 (24%), CML in 619 (29%), and MDS in 260 (12%). There were 1284 males and 830 females with a median age of 35 years (range 16-60 years). Engraftment was achieved in 2065 patients. Among the 1843 patients who survived without relapse at 60 days after transplantation, data with regard to acute GVHD were available in 1819, of whom 537, 308, 91, and 36 developed grade I, II, III, and IV acute GVHD, respectively, with an incidence of grade II-IV acute GVHD of 24%. Pretransplant factors that significantly affected the incidence of grade II-IV acute GVHD were higher age (X40 years old, RR 1.36, 95% CI 1.11-1.66. P ¼ 0.0025) and male sex (RR 1.29, 95% CI 1.04-1.58, P ¼ 0.018). Among the 1566 patients who survived without relapse at 150 days after transplantation, data with regard to chronic GVHD were available in 1514, of whom 705 (47%) developed chronic GVHD including 208 and 270 with limited and extensive chronic GVHD, respectively (grade not described in 227 patients).
Effects of acute GVHD on relapse, nonrelapse mortality, and DFS
The cumulative incidence of relapse and nonrelapse mortality was 23 and 32% at 5 years, respectively, in patients who Table 1 Patients' characteristics Among patients who survived more than 150 days without relapse.
Effect of GVHD on transplant outcome Y Kanda et al developed grade II-IV acute GVHD, and 29 and 12% in those who did not ( Figure 1a ). The development of grade II-IV acute GVHD significantly decreased the incidence of relapse (P ¼ 0.029), but was significantly associated with a greater risk of nonrelapse mortality (Po0.0001). Two factors were identified as independent significant risk factors for relapse by a multivariate analysis using backward stepwise selection of covariates; high-risk disease and the absence of grade II-IV acute GVHD (Table 2a) . However, the benefit of decreased relapse associated with acute GVHD was outweighed by the increased nonrelapse mortality, which produced an inferior DFS at 5 years with grade II-IV acute GVHD in both standard-risk (51 vs 65%, Po0.0001) and high-risk patients (25 vs 32%, P ¼ 0.07) (Figure 2a) . To test the hypothesis that the development of grade I acute GVHD, a form of 'mild' GVHD, may improve transplant outcome, 4, 7 we analyzed the relapse incidence, nonrelapse mortality and DFS, grouped according to the grade of acute GVHD. Nonrelapse mortality at 5 years showed a continuous increase of 9, 17, 26, 39, and 73%, respectively, with increasing acute GVHD grade from 0 to IV (Figure 3b) . Relapse incidence at 5 years tended to be lower with higher acute GVHD grade, but the difference among grade 0, I and II acute GVHD was not statistically significant (31, 26, 27, 16, and 7%, respectively, for grades 0, I, II, III, and IV acute GVHD, Figure 3a) . The development of grade I acute GVHD was associated with an inferior DFS in standard-risk patients (61 vs 68% at 5 years, P ¼ 0.0070, Figure 4a ), but a superior DFS in high-risk patients (43 vs 25% at 5 years, P ¼ 0.018, Figure 4b ). These effects were shown to be independently significant by multivariate analyses (Table 3) .
Effects of chronic GVHD on relapse, nonrelapse mortality, and DFS
The cumulative incidences of relapse and nonrelapse mortality at 5 years were 19 and 18%, respectively, in patients who developed chronic GVHD and 24 and 8% in those who did not (Figure 1b) . Patients who developed chronic GVHD had a lower incidence of relapse (P ¼ 0.023), but had a significantly greater risk of nonrelapse mortality (Po0.0001). High-risk disease and the absence of chronic GVHD were identified as independent significant risk factors for relapse (Table 2b ). However, DFS at 5 years was similar between those who developed chronic GVHD and those who did not (68 vs 71%, P ¼ 0.31 and 41 vs 46%, P ¼ 0.58 for standard-risk and high-risk disease, respectively), since the decreased incidence of relapse was counterbalanced by the increased incidence of nonrelapse mortality (Figure 2b ). The development of limited chronic GVHD, another form of 'mild' GVHD, did not affect survival in either standard-or highrisk patients (76 vs 71% at 5 years, P ¼ 0.39 and 49 vs 46% at 5 years, P ¼ 0.78, respectively ( Figure 5 ).
Effects of the combination of acute and chronic GVHD on DFS
We classified patients into four groups according to the combination of acute and chronic GVHD (no GVHD, acute GVHD alone, chronic GVHD alone, and both acute and chronic GVHD) to evaluate whether a specific combination of acute and chronic GVHD may improve DFS. However, the development of acute GVHD was shown to be associated with inferior survival in both standard-and high-risk patients, regardless of the development of chronic GVHD (Figure 6 ).
Effects of acute and chronic GVHD on relapse and DFS in each disease
The strength of a GVL effect may differ among the underlying diseases. Therefore, we evaluated the effects of acute and chronic GVHD on relapse in each underlying disease to assess whether the development of GVHD may significantly improve transplant outcome in a specific disease. As shown in Table 4 , the antitumor effect was strongest with chronic GVHD in standard-risk AML and MDS, with a marginal significance (P ¼ 0.082 and 0.068, respectively). Neither acute nor chronic GVHD affected the relapse rate of high-risk diseases. We also evaluated the effect of the combination of acute and chronic Effects of the combination of acute and chronic GVHD on DFS in patients who survived more than 150 days without relapse. (a) Standard risk and (b) high risk. Table 4 Effects of acute and chronic GVHD on relapse rate for each hematological malignancy in patients who survived more than 150 days without relapse, stratified by the disease status Effect of GVHD on transplant outcome Y Kanda et al GVHD on DFS, but did not find that acute or chronic GVHD had any benefit on DFS in any disease (data not shown).
Discussion
We evaluated the effects of acute and chronic GVHD on transplant outcome in a relatively homogeneous population, with regard to donor source, graft manipulation, and GVHD prophylaxis. The development of acute and/or chronic GVHD was significantly associated with a decreased risk of relapse, while a benefit in DFS was observed only in patients who developed grade I acute GVHD in high-risk disease. The data confirmed the results from a recent publication of the European Group for Blood and Marrow Transplantation, 14 which were limited to CML, and extended the observations to other leukemias.
We compared the incidence of relapse and DFS in patients who had survived without relapse at a specific landmark time. Without this landmark analysis, patients who died or relapsed too early to develop GVHD would have been included in the non-GVHD group, resulting in a bias toward a favorable outcome in the GVHD group. Therefore, some previous studies might have overestimated the positive impact of 'mild' GVHD on DFS. 4, 7 However, the landmark analysis is not ideal. First, patients who die or relapse before the landmark time do not contribute to the analysis. Second, selection of the landmark may strongly affect the analysis. Therefore, we selected the landmark before the data analysis. The landmark time for acute GVHD analysis was chosen to be day 60 considering the fact that more than 90% of patients who develop grade II-IV acute GVHD do so within 60 days after transplantation. We selected a landmark of day 150 for chronic GVHD analysis, the same as in previous studies. 2, 5 Of course, this analysis of DFS also favors patients who develop GVHD, since more than 80% of GVHDrelated deaths occur within 150 days after transplantation. 15 Nonetheless, we did not find that chronic GVHD conferred any benefit on DFS. We re-evaluated the effect of GVHD using landmark point of 20 and 100 days after transplantation for acute and chronic GVHD, respectively, to rule out the possibility that the selection of landmark point might have strongly affected the results of this study. However, major results did not differ by the changes in the landmark points (data not shown).
The association between relapse incidence and chronic GVHD was prominent in standard-risk AML/MDS, but not in CML. This does not mean that the GVL effect is stronger against AML/MDS than CML. Considering the low incidence of relapse among standard-risk CML patients who did not develop GVHD, this result might indicate that the GVL effect can be obtained without apparent GVHD in standard-risk CML. On the other hand, the fact that there was no relationship between the incidence of relapse and the development of both acute and chronic GVHD might suggest that the GVL effect cannot suppress advanced leukemia. However, considering the finding that grade I acute GVHD improved DFS in high-risk patients, it could be more likely explained by a bias caused by the fact that GVHD more often develops in patients with higher-risk disease. 16 Although we analyzed DFS after stratifying patients according to the disease status, each group may still be heterogeneous, and thus patients who developed GVHD may have included a higher proportion of patients with a relatively higher-risk disease than those who did not. It is also possible that cyclosporine tended to be more rapidly tapered in relatively higher-risk patients based on the earlier studies, 1-4,6,7,17 which might have increased the incidence of GVHD in higher-risk patients and made it difficult to find a beneficial effect of GVHD on relapse incidence. In addition, we must notify that the statistical power was not enough to detect a small effect of GVHD in these subgroup analyses.
The major findings in this study do not support a strategy of inducing GVHD to obtain a GVL effect, and such intervention is not recommended as a routine practice. However, recent studies that have included less-intense GVHD prophylaxis [18] [19] [20] or prophylactic donor lymphocyte infusion 21, 22 to high-risk patients have shown promising results. In addition, a randomized study that compared low-dose CsA at 1 mg/kg/day and high-dose CsA at 5 mg/kg/day showed a better DFS in the lowdose CsA group. 23, 24 The increased incidence of acute GVHD in the low-dose CsA group did not translate into higher transplantrelated mortality. Taking these results together, the impact of GVHD on DFS may differ depending on the GVHD prophylaxis regimen. GVHD induced by less-intense GVHD prophylaxis may be more manageable than GVHD that occurs during standard GVHD prophylaxis.
In conclusion, there appears to be at most a narrow therapeutic window between a decreased incidence of relapse and increased transplant-related mortality due to the development of GVHD. Although this does not deny the possibilities that strategies for inducing a GVL effect by using less-intense GVHD prophylaxis may have beneficial effects, such intervention should be performed only as part of a well-designed clinical study.
